Related Experiment Videos
Intravitreal drug administration with depot devices
1Southwestern Medical Center, Dallas, Texas.
Current Opinion in Ophthalmology
|May 8, 1994
Summary
Sustained ophthalmic drug delivery using depot devices offers a promising alternative to systemic or repeated intravitreal treatments for chronic eye conditions. Current research focuses on nonerodible polymers and microspheres for effective ocular therapeutics.
Area of Science:
- Ophthalmology
- Biomaterials Science
- Drug Delivery Systems
Background:
- Chronic ocular conditions often require long-term treatment.
- Systemic drug administration can cause unwanted side effects.
- Repeated intravitreal injections pose significant risks to patients.
Purpose of the Study:
- To review the current status of sustained drug delivery technologies for posterior segment eye diseases.
- To explore the potential of depot devices as an alternative to conventional ophthalmic treatment methods.
Main Methods:
- Review of existing literature on ocular drug delivery systems.
- Examination of nonerodible polymers (e.g., ethylvinyl acetate/polyvinyl alcohol) and microspheres.
- Mention of osmotic minipump technologies.
Main Results:
- Liposomes have not yet achieved clinical application despite extensive research.
- Nonerodible polymer devices are in advanced Phase III clinical trials.
- Microsphere development for posterior segment disease is under active investigation.
Conclusions:
- Sustained drug delivery via depot devices represents a significant advancement in ocular therapeutics.
- Further development of nonerodible polymers and microspheres holds promise for treating chronic eye diseases like CMV retinitis and proliferative vitreoretinopathy.